Cargando…

Efficacy and safety of sequential immunosuppressive treatment for severe IgA nephropathy: A retrospective study

Background: This study compared the efficacy and safety of sequential immunosuppressive therapy in patients with non-end-stage IgA nephropathy (IgAN) with Lee’s classification of IV ∼ V and provided evidence for the use of immunotherapy in patients with severe IgAN. Methods: We retrospectively analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Mian-Na, Pan, Qingjun, Ye, Ting, Li, Shangmei, Yang, Lawei, Liu, Hua-Feng, Xu, Yongzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043386/ https://www.ncbi.nlm.nih.gov/pubmed/36998610 http://dx.doi.org/10.3389/fphar.2023.1093442

Ejemplares similares

Podocytes are likely the therapeutic target of IgA nephropathy with isolated hematuria: Evidence from repeat renal biopsy
por: Luo, Mian-Na, et al.
Publicado: (2023)

Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis
por: Han, Shisheng, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
por: Zhao, Lijuan, et al.
Publicado: (2023)

The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis
por: Tan, Jiaxing, et al.
Publicado: (2020)

An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective
por: Huang, Xin, et al.
Publicado: (2021)

Immune Characteristics of IgA Nephropathy With Minimal Change Disease
por: Li, Huixian, et al.
Publicado: (2021)

A bibliometric analysis of complement in IgA nephropathy from 1991 to 2022
por: Guo, Yun, et al.
Publicado: (2023)

Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials
por: Zhang, Zheng, et al.
Publicado: (2019)

Astragaloside IV Inhibits Galactose-Deficient IgA1 Secretion via miR-98-5p in Pediatric IgA Nephropathy
por: Liu, Caiqiong, et al.
Publicado: (2021)

Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
por: Kim, Min Jeong, et al.
Publicado: (2016)

Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History
por: Wu, Haiting, et al.
Publicado: (2020)

Efficacy and safety of Telitacicept in patients with IgA nephropathy
por: Liang, Dongrui, et al.
Publicado: (2023)

Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis
por: Liu, Tongtong, et al.
Publicado: (2021)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Continuation of immunosuppressive treatment may be necessary in IgA nephropathy patients with remission of proteinuria: Evaluation by repeat renal biopsy
por: LUO, MIAN-NA, et al.
Publicado: (2014)

Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features
por: Cambier, Alexandra, et al.
Publicado: (2018)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?
por: He, Jia-Wei, et al.
Publicado: (2022)

Case Report: Coexistence of Anti-Glomerular Basement Membrane Disease, Membranous Nephropathy, and IgA Nephropathy in a Female PatientWith Preserved Renal Function
por: Qu, Wei, et al.
Publicado: (2022)

Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy
por: Chen, Tingyu, et al.
Publicado: (2020)

Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?
por: Obrișcă, Bogdan, et al.
Publicado: (2019)

Safety Evaluation of COVID-19 Vaccine in Patients With IgA Nephropathy or IgA Vasculitis Nephritis
por: Zan, Jincan, et al.
Publicado: (2022)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment
por: Feng, Qipu, et al.
Publicado: (2022)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: A retrospective cohort study
por: Jia, Qing, et al.
Publicado: (2022)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

ELL2 Is Downregulated and Associated with Galactose-Deficient IgA1 in IgA Nephropathy
por: Liu, Youxia, et al.
Publicado: (2019)

Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy
por: Chen, Pei, et al.
Publicado: (2018)

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
por: Du, Bing, et al.
Publicado: (2017)

Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study
por: Tang, Chen, et al.
Publicado: (2020)

The predictive value and response to immunosuppressive therapy of IgA nephropathy patients with crescents in a large retrospective Chinese cohort
por: Guo, Yingman, et al.
Publicado: (2023)

Corrigendum: Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome?
por: He, Jia-Wei, et al.
Publicado: (2023)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

Role of immunosuppressive therapy and predictors of therapeutic effectiveness and renal outcome in IgA nephropathy with proteinuria
por: Ruan, Yiping, et al.
Publicado: (2015)

Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
por: Pei, Gaiqin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sglrjmf7lge8msb6ukgvk93au0